# Recurrent Composite Lymphoma in an Elderly Man: A Case of Marginal Zone Lymphoma With Classic Hodgkin Features Treated With Brentuximab and Immunotherapy

## TL;DR

An elderly man with a rare combination of two lymphomas was treated with brentuximab and immunotherapy, highlighting the need for personalized treatment in such cases.

## Contribution

This case adds to the limited literature on composite lymphoma and emphasizes personalized therapy in geriatric patients.

## Key findings

- The patient had a composite lymphoma of marginal zone and classic Hodgkin types.
- Brentuximab was used initially, followed by immunotherapy upon relapse.
- The case underscores the importance of tailored treatment for elderly patients with CL.

## Abstract

Composite lymphoma (CL) is a rare and diagnostically challenging condition where two or more distinct types of lymphoma coexist within the same anatomical site. We report the case of an 82-year-old man with a history of low-grade B-cell lymphoma, now presenting with recurrent disease characterized by a composite histology of marginal zone lymphoma (MZL) and classic Hodgkin's lymphoma (CHL). Management involved single-agent brentuximab due to comorbidities, followed by immune checkpoint inhibition upon relapse. This case illustrates key considerations in the diagnosis, staging, and treatment of CLs in geriatric patients. The clinical course further highlights the importance of personalized therapy selection based on age, comorbidities, and histological features. This case also contributes to the limited literature on real-world outcomes in patients with CL and underscores the need for future prospective studies and biomarker-driven treatment approaches in this rare entity.